Ultromics Raises $55M to Scale AI Cardiology Platform for Heart Failure Detection

Ultromics, a pioneer in AI-driven cardiology solutions, has closed $55M in Series C financing to expand its technology for detecting hard-to-diagnose forms of heart failure. The round was co-led by L&G, Allegis Capital, and Lightrock, with continued participation from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Notable new investors include major U.S. health systems such as University of Chicago Medicine and UCM Ventures.

The company's FDA-cleared EchoGo® platform represents the first Medicare-reimbursed AI technology designed to help clinicians detect HFpEF (Heart Failure with preserved Ejection Fraction) and cardiac amyloidosis. These conditions represent two of the most challenging forms of heart failure to diagnose, with up to 64% of HFpEF cases going undetected and cardiac amyloidosis frequently mistaken for more common heart diseases.

Heart failure poses a mounting healthcare challenge in the United States, with annual costs exceeding $30 billion and projections reaching $70 billion by 2030. The diagnostic challenges are particularly acute for HFpEF and cardiac amyloidosis, where traditional echocardiogram interpretation often fails to identify subtle disease signals. This leads to delayed treatment and worse patient outcomes as conditions progress undetected.

Ultromics addresses these diagnostic gaps by applying AI to standard echocardiograms, extracting previously hidden disease indicators without requiring new hardware or workflow disruptions. The platform generates real-time probability scores that enable cardiologists to identify high-risk patients earlier than conventional methods allow. Having analyzed over 430,000 echocardiograms to date, the company has demonstrated significant clinical impact.

In clinical studies, EchoGo® improved HFpEF detection by 73.6% compared to standard clinical risk scores. The platform's cardiac amyloidosis diagnostic model, validated across 18 institutions in a global study published in the European Heart Journal, outperformed existing clinical risk scores while accurately distinguishing the disease from similar conditions.

"The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis."

The new funding will support Ultromics' expansion across U.S. hospitals and echo labs serving high volumes of at-risk patients. The company plans to extend its diagnostic pipeline to include additional cardiac conditions while developing new distribution channels and deepening partnerships with health systems and clinical leaders. With full Medicare reimbursement already in place, the platform is positioned for rapid scaling across hospitals, clinics, and health systems nationwide.